Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples